Page last updated: 2024-10-23

benserazide and Fever of Unknown Origin

benserazide has been researched along with Fever of Unknown Origin in 1 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Fever of Unknown Origin: Fever in which the etiology cannot be ascertained.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Che, NN1
Chen, SY1
Li, X1
Ma, JJ1
Yang, HQ1

Other Studies

1 other study available for benserazide and Fever of Unknown Origin

ArticleYear
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
    Journal of neuroimmunology, 2021, 12-15, Volume: 361

    Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benser

2021